Details

Autor(en) / Beteiligte

• Burdett, Sarah
• Boevé, Liselotte M.
• Ingleby, Fiona C.
• Fisher, David J.
• Rydzewska, Larysa H.
• Vale, Claire L.
• van Andel, George
• Clarke, Noel W.
• Hulshof, Maarten C.
• James, Nicholas D.
• Parker, Christopher C.
• Parmar, Mahesh K.
• Sweeney, Christopher J.
• Sydes, Matthew R.
• Tombal, Bertrand
• Verhagen, Paul C.
• Tierney, Jayne F.

Titel

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

Ist Teil von

• European urology, 2019-07, Vol.76 (1), p.115-124

Ort / Verlag

Switzerland: Elsevier B.V

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). To systematically review trials of prostate radiotherapy. Using a prospective framework (framework for adaptive meta-analysis [FAME]), we prespecified methods before any trial results were known. We searched extensively for eligible trials and asked investigators when results would be available. We could then anticipate that a definitive meta-analysis of the effects of prostate radiotherapy was possible. We obtained prepublication, unpublished, and harmonised results from investigators. We included trials that randomised men to prostate radiotherapy and androgen deprivation therapy (ADT) or ADT only. Hazard ratios (HRs) for the effects of prostate radiotherapy on survival, progression-free survival (PFS), failure-free survival (FFS), biochemical progression, and subgroup interactions were combined using fixed-effect meta-analysis. We identified one ongoing (PEACE-1) and two completed (HORRAD and STAMPEDE) eligible trials. Pooled results of the latter (2126 men; 90% of those eligible) showed no overall improvement in survival (HR=0.92, 95% confidence interval [CI] 0.81–1.04, p=0.195) or PFS (HR=0.94, 95% CI 0.84–1.05, p=0.238) with prostate radiotherapy. There was an overall improvement in biochemical progression (HR=0.74, 95% CI 0.67–0.82, p=0.94×10−8) and FFS (HR=0.76, 95% CI 0.69–0.84, p=0.64×10−7), equivalent to ∼10% benefit at 3yr. The effect of prostate radiotherapy varied by metastatic burden—a pattern consistent across trials and outcome measures, including survival (<5, ≥5; interaction HR=1.47, 95% CI 1.11–1.94, p=0.007). There was 7% improvement in 3-yr survival in men with fewer than five bone metastases. Prostate radiotherapy should be considered for men with mHSPC with a low metastatic burden. Prostate cancer that has spread to other parts of the body (metastases) is usually treated with hormone therapy. In men with fewer than five bone metastases, addition of prostate radiotherapy helped them live longer and should be considered. This prospectively designed systematic review showed that prostate radiotherapy did not improve survival in unselected men. A difference in effect by metastatic burden was evident across included trials and outcomes; 3-yr survival increased by 7% in men with fewer than five bone metastases.